Advertisement

Chemotherapy pp 277-283 | Cite as

Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors

  • Victor A. Levin
  • Charles B. Wilson

Abstract

The nitrosoureas have been in clinical usage in the treatment of primary and secondary brain tumors since 1969. Either as a tribute to the activity of these drugs or as an example of our ineptness in discovering other active drugs, the nitrosoureas, particularly BCNU, remain our most active agents.

Keywords

Brain Tumor Malignant Glioma Brain Tumor Model Secondary Brain Tumor Brain Tumor Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wheeler GP: Recent advances in the biochemical pharmacology of selected alkylating agents. Transplant Proc. 5:1167–1170, 1973.PubMedGoogle Scholar
  2. 2.
    Montgomery JA and Struck RF: The relationship of the metabolism of anticancer agents to their activity. Prog Drug Res 17:320–409, 1973.PubMedGoogle Scholar
  3. 3.
    Wheeler GP, Bowdon BJ, Grimsley JA, et al.: Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas. Cancer Res 34:194–200, 1974.PubMedGoogle Scholar
  4. 4.
    Levin VA and Wilson CB: Pharmacological considerations in brain tumor chemotherapy. IN: Brain Turno Chemotherapy, D Fewer, CB Wilson, VA Levin (eds) Charles C Thomas, Springfield, Chapter 3 (in press).Google Scholar
  5. 5.
    Levin VA and Wilson CB: Chemotherapy: The agents in current use. Seminars in Oncology 2:63–67, 1975.PubMedGoogle Scholar
  6. 6.
    Kumar AVR, Renaudin J, Wilson CB, Boldrey EB, Enot KJ and Levin VA: Phase II study of N-isopropyl-0C-2(methyl-hydrazine)-toluamide hydrochloride (Matulane, Procarbazine HCl; NSC-77213) in the treatment of brain tumors. J Neurosurg 40:365–371, 1974.CrossRefGoogle Scholar
  7. 7.
    Gutin PH, Wilson CB, Kumar AVR, Boldrey EB, Levin VA, Powell M, and Enot KJ: Phase II study of procarbazine, CCNU and vincristine combination therapy in the treatment of malignant brain tumors. Cancer 35:1398–1404, 1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Levin VA, Crafts D, Wilson CB, Boldrey EB, Enot KJ, Pischer T, and Seager M: A phase II study of BCNU-Procarbazine in recurrent malignant gliomas (in preparation).Google Scholar
  9. 9.
    Crafts D, Wilson CB, Levin VA, Boldrey EB, Pischer T, and Enot KJ: Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU and vincristine (submitted).Google Scholar
  10. 10.
    Wheeler, KT, Tel N, Williams M, Sheppard S, Levin VA, and Kabra PM: Factors influencing the survival of rat brain tumor cells following in vitro treatment with 1,3 bis(2-chloroethyl)-1-nitrosourea (BCNU). Cancer Res 35:1464–1469, 1975.PubMedGoogle Scholar
  11. 11.
    Rosenblum ML, Wheeler KT, Wilson CB, Barker M, and Knebel KD: In vitro evaluation of in vivo brain tumor chemotherapy with 1,3 bis(2-chloroethyl)-1-nitrosourea (BCNU). Cancer Res 35: 1387–1391, 1975.PubMedGoogle Scholar
  12. 12.
    Levin VA and Kabra PM: Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep 58:787–792, 1974.PubMedGoogle Scholar
  13. 13.
    Levin VA and Kabra PM: Brain and tumor pharmacokinetics of BCNU and CCNU following i.v. and intracarotid artery (i.e.a.) administration. Proc Amer Assoc Cancer Res 16:19, 1975.Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Victor A. Levin
    • 1
  • Charles B. Wilson
    • 1
  1. 1.Department of NeurosurgeryUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations